Nov 3, 2024, 16:08
Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer
Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X about a recent paper by Florentine Hilbers et al. published in NPJ Breast Cancer:
“Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative Breast Cancer.
In clinically low-risk (T<1cm, N0) HR+/HER2- patients, there is no benefit of adjuvant chemotherapy in genomically high-risk patients according to MammaPrint.”
Authors: Florentine Hilbers, Coralie Poncet, Konstantinos Tryfonidis, Laura van ’t Veer, Fatima Cardoso et al.
More posts featuring Yakup Ergün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43